INTRODUCTION
============

Chemotherapy-induced nausea and vomiting (CINV) is one of the most troublesome adverse effects of cancer treatment, with a significant negative impact on quality of life.^[@b1]-[@b3]^ Several new treatments for CINV have been introduced and are now recommended in evidence-based antiemetic guidelines developed by ASCO,^[@b4]^ the European Society of Medical Oncology (ESMO) and Multinational Association of Supportive Care in Cancer (MASCC),^[@b5]^ and the National Comprehensive Cancer Network (NCCN).^[@b6]^ Although guideline-recommended therapies significantly reduce the risk of CINV, such regimens often are underused in CINV prevention.^[@b7]^

Until recently, little has been documented about the prevalence and management of CINV in the Asia-Pacific region or the applicability of international CINV management guidelines to Asian populations. International guidelines are mostly based on studies conducted in white patients, but ethnic differences and genetic polymorphisms may contribute to CINV and affect the utility of antiemetic treatment.^[@b3],[@b8]-[@b11]^

To optimize prevention and management of CINV in Asian patients, regional guidelines should take into account ethnic variations in CINV risk as well as differences in health care systems, clinical practice, and treatment availability and affordability. A meeting of experts from Malaysia, the Philippines, and Singapore was convened in Manila, Philippines, on November 24, 2014, to assess the local applicability of international CINV management guidelines and to develop regionally appropriate modifications. Principal considerations were current clinical practice, treatment availability and affordability, and specifics of local health care systems. This article describes consensus-based outcomes from the discussions at the Manila meeting.

DISCUSSION
==========

Burden of CINV in Asia
----------------------

Several publications provide insight into CINV characteristics and treatment in the Asia-Pacific region.^[@b12]-[@b17]^ Observational studies in Malaysia, the Philippines, and Singapore indicate that nausea occurs more frequently than vomiting ([Table 1](#tbl1){ref-type="table"}). However, the definitions for nausea and vomiting vary among studies, which makes comparison of the incidence difficult.
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The following risk factors for CINV are the same in Southeast Asia as in Europe:Type of chemotherapy administered. In a study conducted among patients with head and neck cancer in Singapore, single-day rather than multiday cisplatin therapy was associated with a 1.5-fold increase in the risk of nausea.^[@b12]^CINV experienced during previous chemotherapy.^[@b12],[@b14],[@b18]^ In a multinational, prospective, observational study in patients who received highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC), previous CINV was a significant predictor of subsequent vomiting and clinically significant nausea and/or vomiting.^[@b18]^Nonadherence to antiemetic therapy. In a large, prospective study of patients with breast cancer who received anthracycline-based chemotherapy in Singapore, nonadherent patients were less likely to achieve complete CINV control than adherent patients (*P* = .048).^[@b19]^Anxiety and history of motion sickness*.* A study of patients who received doxorubicin and cyclophosphamide for breast cancer found that anxiety predicted development of acute (*P* = .004) and delayed nausea (*P* = .024) and that a history of motion sickness predicted delayed vomiting (*P* = .047).^[@b14]^Concomitant radiotherapy and poor performance status. Among 235 patients treated with cisplatin-based regimens for head and neck cancer, concomitant radiotherapy was associated with nausea (*P* = .022), and patients with an Eastern Cooperative Oncology Group score ≥ 1 were 2.4 times more likely to experience vomiting (*P* = .046) than patients with a score of 0.^[@b12]^Female sex and younger than 50 years of age*.* The Pan Australasia Chemotherapy-Induced Emesis (PrACTICE) study conducted in Asian countries evaluated 648 patients who received HEC or MEC. Female versus male patients were less likely to have a complete response (no vomiting or use of rescue antiemetic therapy) during chemotherapy cycles two and three (*P* \< .001). Patients younger than 50 years of age were more likely (*P* ≤ .004) to experience CINV in cycles two and three than older patients.^[@b18]^Cancer-related fatigue*.* Poon et al^[@b20]^ evaluated cancer-related fatigue scores in 473 patients with GI or breast cancers. Patients with lower versus higher fatigue interference scores were more likely to have a complete response to antiemetics (odds ratio, 1.57; *P* = .027).^[@b20]^Genetic polymorphisms in the *ABCB1* transporter gene. Particular haplotypes of the *ABCB1* gene are associated with an increased risk of CINV.^[@b9]-[@b11]^ In Indonesia, the CTG haplotype is associated with an increased risk of delayed CINV in patients who receive HEC.^[@b10]^ Similarly, the *ABCB1* CG haplotype is associated with an increased risk of acute CINV in Chinese patients during high-dose cytarabine for acute myeloid leukemia,^[@b11]^ and the 3435C\>T polymorphism is a risk factor for acute CINV in Japanese women who receive chemotherapy for breast cancer.^[@b9]^

Low rates of alcohol use have been reported in Asian patients with cancer,^[@b21],[@b22]^ and a history of low alcohol consumption has been linked with chemotherapy-induced emesis.^[@b23]^ However, knowledge is limited about the impact of alcohol use on CINV in daily clinical practice.^[@b24]^

Antiemetic Therapy: Use of Guidelines and Prescribing Patterns in Asia
----------------------------------------------------------------------

The clinical management of CINV in the Asia-Pacific has been investigated as part of the PrACTICE study, a prospective, observational study conducted in Australia, China, India, Singapore, South Korea, and Taiwan.^[@b25]^ In PrACTICE, 84% of physicians regularly used antiemetic guidelines, with NCCN guidelines consulted by 65% of physicians, and MASCC/ESMO guidelines by 39%.^[@b26]^ Almost all physicians (97%) considered guidelines to be useful for CINV management.^[@b26]^

A high rate of serotonin (5-hydroxytryptamine-3 \[5-HT~3~\]) antagonist use (96% to 97%) is evident in patients who receive HEC or MEC, but the prescribing of other antiemetic therapies varies markedly among countries.^[@b26]^ Among patients who have received HEC, 95% in Australia also received corticosteroids, but only 70% in China did; corresponding rates of neurokinin-1 (NK~1~) antagonist use were 91% and 0%, respectively. NK~1~ antagonist prescribing was probably affected by international differences in drug availability and reimbursement, whereas reasons for underuse of corticosteroids are less clear.^[@b26]^

The PrACTICE study showed that corticosteroids generally are underprescribed in Asian patients, particularly in the delayed phase after HEC and MEC.^[@b26]^ Some prescribers may not be aware of the guideline recommendations for corticosteroids, have concerns about the potential adverse effects of administering corticosteroids for 3 to 4 days, and/or lack confidence in these drugs' antiemetic efficacy.^[@b26]^ Underuse of corticosteroids may also be partly related to cultural perceptions and corticosteroid aversion in Asian patients.^[@b19],[@b26],[@b27]^ Dexamethasone is inexpensive, so to overcome barriers to its use would improve CINV prophylaxis without significant additional treatment costs.^[@b26]^ Asia-specific CINV management recommendations may help to overcome barriers to corticosteroid use and support rational use of NK~1~ antagonists as they become more readily available.

Consensus Development Process
-----------------------------

The Manila panel discussed NCCN^[@b6]^ and MASCC/ESMO^[@b5]^ recommendations and their applicability to Southeast Asia. These guidelines were selected because they are the most widely used in the region.^[@b26]^ For each recommendation, the panel voted on the level of confidence and level of consensus. Level of confidence (high, moderate, or low) was based on the panel's assessment of the strength of the published evidence to support that recommendation. Consensus was defined as high for seven votes, moderate for five or six votes, and low for three or four votes. The panel also developed specific recommendations for resource-limited settings so that guidance could be provided for oncologists who practice in areas with limited access to newer and/or more costly antiemetics.

Resource-restricted settings were defined as having the capacity to offer basic core antiemetic therapy and any other antiemetic drugs that are attainable with restricted financial means and basic infrastructure. Higher-level resource settings were defined as having the capacity to offer important antiemetic therapy that would be difficult to attain and would not be standard therapy in a resource-restricted setting but that may be recommended in international guidelines regardless of resource constraints.

Since the Manila meeting in 2014, the MASCC guidelines have been updated.^[@b28]^ Therefore, the updated MASCC guidelines have been reviewed, and an additional literature search of PubMed was conducted in July 2016 that used the search term CINV to identify any other relevant evidence, with a focus on studies conducted in the Asia-Pacific.

The consensus reached in 2014 remains essentially unchanged except where indicated. Several agents added to the 2016 MASCC/ESMO guidelines^[@b28]^ (rolapitant, netupitant plus palonosetron combination) were not available in the Asia-Pacific at the time this article was submitted.

SUMMARY
=======

Emetogenic Chemotherapies
-------------------------

NCCN^[@b6]^ and MASCC/ESMO^[@b5]^ guidelines both stratified recommendations according to the emetogenic potential of chemotherapies. The Manila panel agrees with the NCCN classification of HEC or MEC intravenous agents,^[@b6]^ with some modifications ([Table 2](#tbl2){ref-type="table"}).
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The panel recommends that cisplatin dosages \> 50 mg/m^2^ be included in the HEC classification (high confidence; high consensus), whereas NCCN and MASCC/ESMO guidelines characterize cisplatin as highly emetogenic, irrespective of dosage.^[@b5],[@b6],[@b28]^ Although cisplatin generally is administered at a dosage of \> 50 mg/m^2^, lower dosages sometimes are used (eg, in combination with radiotherapy). Because evidence of a dose-related effect of cisplatin on CINV exists,^[@b12]^ the panel defines appropriate CINV management recommendations for patients who receive cisplatin \< 50 mg/m^2^.

The panel also advocates a separate classification for anthracycline plus cyclophosphamide (AC) combination regimens (high confidence; high consensus). Both the NCCN and 2016 MASCC/ESMO guidelines classify AC combinations as HEC.^[@b6],[@b28]^ The earlier MASCC/ESMO recommendations classified anthracyclines as MEC, irrespective of dosage, and cyclophosphamide as HEC (at dosages ≥ 1,500 mg/m^2^) or MEC (\< 1,500 mg/m^2^).^[@b28]^

Daunorubicin and idarubicin are listed as MECs, regardless of dosage, in the NCCN guidelines,^[@b6]^ whereas doxorubicin and epirubicin are documented as HEC or MEC, which depends on dosage. NCCN also acknowledges that some anthracyclines (daunorubicin, doxorubicin, epirubicin) may be highly emetogenic in some patients; cyclophosphamide alone is categorized as HEC at dosages \> 1,500 mg/m^2^ or MEC at doses ≤ 1,500 mg/m^2^.^[@b6]^

The panel recommends that AC combinations be labeled as a separate emetogenic category. Such categorization permits specific antiemetic treatment recommendations to be made, which closely reflect regional clinical practice (see the section on antiemetic prophylaxis in patients who receive AC).

The panel concurs with the following NCCN categories for other emesis risk groups (low confidence; high consensus): intravenous agents with low or minimal emetogenicity and oral agents with minimal to low or moderate to high emetic risk^[@b6]^ ([Table 2](#tbl2){ref-type="table"}). The emetogenic risk for oral antineoplastic agents is largely based on consensus and data from registration trials in which patients often received antiemetic prophylaxis.^[@b5]^ Oncologists should therefore be aware of the low level of confidence in emetogenic classification for newer antineoplastics, particularly oral agents.

Antiemetic Prophylaxis
----------------------

The Manila panel developed recommendations for antiemetic use in the prevention and treatment of acute and delayed CINV in patients who receive various types of chemotherapy in general and resource-restricted settings ([Table 3](#tbl3){ref-type="table"}). With regard to resource stratification, treatment choice is driven not only by drug acquisition cost but also by factors such as the overall cost-effectiveness of antiemetic schedules, the potential for longer hospital stays as a result of complications, patient loss of income, patient willingness to pay, unexpected hospital visits to control CINV between cycles, and potentially increased costs to families if the patient needs additional care.
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Patients Who Receive HEC
------------------------

### Acute CINV.

In most clinical settings, the panel suggests triple therapy with a 5-HT~3~ antagonist (preferably palonosetron), dexamethasone, and aprepitant (high confidence; high consensus). Support for this recommendation stems from data from randomized, double-blind studies (including one in Chinese patients) in which a 5-HT~3~ antagonist plus dexamethasone and aprepitant was superior to a 5-HT~3~ antagonist plus dexamethasone in completely controlling CINV in patients treated with HEC.^[@b29],[@b30]^ In a trial in 411 Asian patients, the complete response rate was significantly greater with triple versus dual therapy during the overall phase (0 to 120 hours after initiation of HEC; 69.6% *v* 57.0%; *P* = .007) and the delayed phase (25 to 120 hours after initiation of HEC; 74.0% *v* 59.4%; *P* \< .001).^[@b30]^ In contrast to a study in non-Asian patients, complete response rates during the acute phase (0 to 24 hours after initiation of HEC) were not significantly different for triple versus dual therapy (79% for both regimens). The relatively high acute phase complete response rate observed in Asian patients treated with dual therapy may have concealed the advantage of triple therapy observed in non-Asian patients.^[@b29],[@b30]^

Palonosetron is the recommended 5-HT~3~ antagonist. A meta-analysis of five randomized studies in 2,057 patients showed that those treated with palonosetron rather than dolasetron, granisetron, or ondansetron had a significantly reduced relative risk of acute nausea (--14%; *P* = .007), delayed nausea (--18%; *P* \< .001), acute vomiting (--24%; *P* \< .001), and delayed vomiting (--24%; *P* \< .001).^[@b31]^ In addition, palonosetron has a stronger binding affinity at 5-HT~3~ receptors and a longer half-life (approximately 40 hours) than other 5-HT~3~ antagonists.^[@b32]^ These findings explain the clinical rationale for palonosetron to prevent acute and delayed CINV.

The recommended dosage of aprepitant in Southeast Asia is 125 mg orally 1 hour before chemotherapy.^[@b33]^ NCCN guidelines list either aprepitant or fosaprepitant as appropriate NK~1~ antagonists for use in triple therapy schedules.^[@b6]^ The 2016 MASCC/ESMO guidelines recommend aprepitant, fosaprepitant, rolapitant, or netupitant (available in combination with palonosetron),^[@b28]^ but the latter two agents are not yet available in the Asia-Pacific.

In resource-restricted settings, triple therapy is still recommended, although it is more expensive than dual therapy. Data from Asia, including Singapore, show that the additional acquisition cost of aprepitant is largely offset by reduced rescue medication use, hospitalization, and overall patient management costs.^[@b34],[@b35]^ However, if the acquisition cost of aprepitant precludes its use as part of a triple therapy regimen in resource-limited settings, olanzapine is an acceptable alternative,^[@b6]^ although further studies are needed on the role of olanzapine to prevent CINV in patients who receive HEC.

No specific cost-effectiveness data support the use of palonosetron in resource-restricted settings. Thus, another 5-HT~3~ antagonist may be used as a triple therapy constituent in patients who receive HEC (high confidence; high consensus). If patients do not respond to one 5-HT~3~ antagonist, another with a different metabolic pathway can be tried because genetic polymorphisms in cytochrome P450 (CYP) isoenzymes may lead to interpatient differences in drug metabolism and bioavailability.^[@b36]^ [Table 4](#tbl4){ref-type="table"} lists the 5-HT~3~ antagonists typically used in Southeast Asia.^[@b5],[@b36],[@b37]^
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### Delayed CINV.

In all clinical settings in Southeast Asia, the panel recommends the use of dual therapy with dexamethasone (days 2 to 4) and aprepitant (days 2 to 3) to prevent delayed CINV (high confidence; high consensus), if resources allow. Clinicians must not use aprepitant on days 2 to 3 if it was not used on day 1 because this is ineffective and wasteful. If aprepitant was not used on day 1, the recommended regimen for preventing delayed CINV is dexamethasone monotherapy.

Typically, 5-HT~3~ antagonists are less effective in preventing delayed than acute CINV. A large meta-analysis revealed that the addition of a 5-HT~3~ antagonist (dolasetron, granisetron, or ondansetron) to dexamethasone does not significantly improve the antiemetic efficacy of dexamethasone alone.^[@b38]^ Therefore, use of oral 5-HT~3~ antagonists for the prevention of delayed CINV is not recommended.

Although metoclopramide may be a low-cost alternative to aprepitant for delayed CINV prevention,^[@b39]^ equivalent efficacy has not been demonstrated at doses approved for use in the Asia Pacific, where a maximum metoclopramide dose of 10 mg three times per day is recommended to reduce the risk of neurologic and other dose-related adverse drug reactions.^[@b40]^

Patients Who Receive MEC
------------------------

### Acute CINV.

The Manila panel recommends dual therapy with a 5-HT~3~ antagonist, preferably palonosetron, and dexamethasone in patients treated with MEC in most clinical settings in Southeast Asia (moderate confidence; high consensus). Palonosetron is the preferred 5-HT~3~ antagonist because data from multicenter, randomized, double-blind trials have demonstrated superior antiemetic efficacy relative to dolasetron^[@b41]^ and ondansetron^[@b42]^ in patients who receive MEC. A meta-analysis of five studies in 2,057 patients treated with HEC or MEC revealed that palonosetron is significantly superior to dolasetron, granisetron, and ondansetron in preventing both acute and delayed CINV.^[@b31]^ Limited evidence supports adding aprepitant to combination therapy in patients who receive MEC, and the panel recommends that oral aprepitant 125 mg^[@b33]^ only be added to dual therapy (palonosetron + dexamethasone) in subsequent cycles if CINV is not well controlled by dual therapy in cycle 1; aprepitant should not be used in the first cycle (moderate confidence; high consensus). MECs are not considered emetogenic enough to warrant routine aprepitant use in patients who receive these regimens. In an observational study in Singapore in 156 patients treated with capecitabine plus oxaliplatin (which is moderately emetogenic), 88% had no emesis during dual therapy with a 5-HT~3~ antagonist and dexamethasone.^[@b17]^

In resource-limited settings, any of the available 5-HT~3~ antagonists can be used in combination with dexamethasone to prevent acute CINV in patients treated with MEC, but aprepitant should not because it lacks cost-effectiveness when used with MEC (high confidence; high consensus). Olanzapine is a low-cost alternative to aprepitant if triple therapy is indicated,^[@b6]^ although further studies are needed on the preventive efficacy of olanzapine in patients who receive MEC.

### Delayed CINV.

In most clinical settings, the panel recommends monotherapy with a corticosteroid on days 2 and 3 to prevent delayed emesis; if aprepitant is used on day 1, it should be continued on days 2 and 3 (high confidence; high consensus). Corticosteroids, which are inexpensive and effective in preventing delayed CINV, are the preferred treatment in resource-limited settings (high confidence; high consensus); a 5-HT~3~ antagonist is a rational alternative for patients who cannot tolerate corticosteroids.

Patients Who Receive AC Combinations
------------------------------------

### Acute CINV.

Patients who receive AC combination therapy should be treated with a 5-HT~3~ antagonist (preferably palonosetron) and dexamethasone; oral aprepitant 125 mg can be added in centers without limited resources (moderate confidence; high consensus). In resource-limited centers, the incremental benefit of aprepitant may not justify the cost. An observational study of 91 patients who received AC in Singapore found that most patients tolerated AC chemotherapy moderately well without vomiting.^[@b14]^ These patients received CINV prophylaxis according to institutional guidelines, which recommended a 5-HT~3~ antagonist plus corticosteroid during cycle 1 to prevent acute CINV and a 5-HT~3~ antagonist plus corticosteroid plus dopamine antagonist to prevent delayed CINV. Patients who experienced CINV (acute or delayed) during cycle 1 were given concomitant aprepitant during the next cycle, but only nine patients required aprepitant in cycle 2.^[@b14]^ Thus, aprepitant should not be used routinely to prevent acute CINV in patients treated with AC in Asia (moderate confidence; high consensus), but further studies are required. If triple therapy is considered necessary, an acceptable low-cost option is olanzapine with a 5-HT~3~ antagonist and dexamethasone.^[@b6]^

### Delayed CINV.

Typically, corticosteroid dosages used in Southeast Asia ([Table 5](#tbl5){ref-type="table"}) are lower than those advocated in international guidelines for CINV management.^[@b5],[@b6]^ Thus, the panel recommends therapy with dexamethasone 8 mg on days 2 to 3 to prevent delayed emesis in patients treated with AC in most settings. If resources allow, aprepitant 80 mg may be added, with the proviso that aprepitant should be used in the delayed (days 2 to 3) antiemetic schedule only if used previously on day 1 (moderate confidence; high consensus). Alternative strategies in resource-limited settings include an olanzapine-based regimen.^[@b6]^
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Corticosteroid-sparing regimens may be another option in resource-limited settings. In women who receive AC regimens for breast cancer, a corticosteroid-sparing regimen (single dose of palonosetron then dexamethasone on day 1 only) was no less effective in preventing delayed CINV than continuation of dexamethasone for 3 days.^[@b43]^

Patients Who Receive Multiday Cisplatin
---------------------------------------

Multiday treatment with highly emetogenic schedules presents unique challenges for CINV prevention because patients may experience both acute and delayed CINV, and the risk periods may overlap, depending on the chemotherapy schedules used.^[@b6]^ Antiemetic therapy, therefore, should be individualized and practical issues considered (eg, administration in the inpatient *v* outpatient setting, preferred route of administration, duration of antiemetic action, tolerability profile, likely patient adherence to treatment).^[@b6]^ Recommendations from the Manila panel should be regarded as general guidance only.

### Acute CINV.

In unrestricted resource settings in Southeast Asia, patients treated with multiday cisplatin should receive triple therapy with palonosetron, dexamethasone, and aprepitant to prevent acute CINV. Data that support aprepitant use come from a randomized, placebo-controlled, crossover study in 69 patients with testicular cancer who received a 5-day cisplatin-based schedule.^[@b44]^ The addition of aprepitant to dexamethasone plus a 5-HT~3~ antagonist significantly improved the complete response rate (42% *v* 13% for triple *v* dual therapy, respectively; *P* \< .001).^[@b44]^ However, aprepitant was scheduled over days 3 to 7 of therapy, which differs from the currently approved 3-day dosing regimen of aprepitant. Further studies are required to establish the role and schedule of aprepitant in multiday cisplatin chemotherapy.

In resource-limited environments, an inexpensive 5-HT~3~ antagonist should be used instead of palonosetron, and aprepitant should be removed from the triple therapy regimen (moderate confidence; moderate consensus). This recommendation is substantiated by a study conducted by Chan et al^[@b12]^ in which 45 patients who received multiday (over 5 days) cisplatin received granisetron and dexamethasone (without aprepitant) as antiemetic prophylaxis. Nausea and vomiting were well controlled with 44.4% and 28.9% patients who experienced significant nausea and vomiting, respectively. Triple therapy with olanzapine, a 5-HT~3~ antagonist, and dexamethasone is an acceptable and inexpensive alternative.

### Delayed CINV.

5-HT~3~ antagonists generally are less effective in the management of delayed versus acute CINV.^[@b6],[@b45]^ Thus, to prevent delayed CINV in patients treated with multiday cisplatin-containing schedules, the panel recommends dexamethasone; aprepitant can be added where resources permit (moderate confidence; high consensus).

Chemotherapy With Low or Minimal Emetogenic Risk
------------------------------------------------

For patients who receive chemotherapy with low emetogenic potential, physicians in the Asia-Pacific should consider the omission of antiemetics to prevent acute CINV. Should antiemetics be considered appropriate, the Manila panel recommends monotherapy with a 5-HT~3~ antagonist, dexamethasone, or a dopamine-receptor antagonist (eg, metoclopramide) to prevent acute CINV (low confidence; high consensus); however, limited evidence for this approach exists. Adding a 5-HT~3~ antagonist to single-agent therapy with dexamethasone or metoclopramide is not cost-effective in this setting.^[@b46]^

No routine prophylaxis is needed to prevent delayed CINV in patients who receive chemotherapy with low emetogenic potential or to prevent acute or delayed CINV in patients who receive chemotherapy with minimal emetogenic potential (high confidence; high consensus). However, these patients should be closely monitored; antiemetic therapy should be administered promptly if CINV occurs.

Anticipatory CINV
-----------------

Effective control of CINV in the first cycle of chemotherapy is essential because patients who experience CINV during cycle 1 are more likely to have anxiety and anticipatory nausea before subsequent cycles.^[@b47]^ Patients with anticipatory nausea and vomiting may benefit from behavioral therapies (high confidence; moderate consensus). Benzodiazepines are the only agents that have been shown to reduce the incidence of anticipatory nausea and vomiting, but their efficacy tends to decrease as chemotherapy continues (moderate confidence; low consensus).

Breakthrough/Refractory CINV
----------------------------

Despite the use of recommended prophylaxis, CINV may still develop in some patients. Recommendations for these patients are listed in [Table 6](#tbl6){ref-type="table"}. Patients with breakthrough CINV may benefit from switching antiemetic agents (eg, from one 5-HT~3~ antagonist to another).^[@b6],[@b48]^ Evidence supports interracial differences in genetic polymorphisms for CYP enzymes, which may affect the metabolism of various 5-HT~3~ antagonists, even between Asian populations.^[@b36]^ Similarly, polymorphisms in the gene for the ABCB1 efflux transporter may affect the rate at which various 5-HT~3~ antagonists cross the blood-brain barrier and, therefore, their antiemetic efficacy.^[@b9]-[@b11]^ This may explain some differences between racial groups or between individuals within the same racial group in the clinical effects of certain 5-HT~3~ antagonists.^[@b9]-[@b11],[@b36],[@b49]^ For switching between 5-HT~3~ antagonists, it is advisable to choose an agent metabolized by a different CYP enzymatic pathway and to use pharmacogenomic information on the patient's *ABCB1* haplotype, if available.
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If a switch is not effective or feasible, the addition of an agent from a different class, such as a dopamine antagonist,^[@b50]^ olanzapine,^[@b51]^ benzodiazepine,^[@b6]^ or phenothiazine, is recommended.^[@b6]^ Olanzapine has been shown to be more effective than metoclopramide in this setting.^[@b51]^

In conclusion, effective CINV management is best achieved by a multidisciplinary team, including oncologists, pharmacists, and nurses.^[@b13],[@b52]^ Through consultation and collaboration, better prescribing choices can be made for patients with cancer^[@b53]^ that take into account the emetogenic risk associated with various chemotherapy schedules, specific patient characteristics, and pharmacologic and clinical profiles of antiemetic agents.

The current recommendations for CINV management in Southeast Asia are unique because of their explicit regional focus and provide guidance for resource-limited centers. The cost-effectiveness of various antiemetic regimens needs to be evaluated to refine these recommendations for resource-limited settings. Meanwhile, the consensus outlined here is anticipated to contribute to improvements in CINV management in Asia.
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